NervGen Pharma to Participate at Upcoming Investor Conferences

Core Insights - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic conditions [5] Upcoming Investor Conferences - NervGen's executive leadership team, including CEO Adam Rogers, will participate in multiple investor conferences in 2026 [1] - The Oppenheimer 36th Annual Healthcare Life Sciences Conference will take place on February 25-26, 2026, with NervGen's presentation scheduled for February 25 from 12:40 to 1:10 pm ET [2] - The TD Cowen 46th Annual Health Care Conference is set for March 2-4, 2026, with NervGen presenting on March 2 from 2:30 to 3:00 pm ET [3] - The Leerink Partners Global Healthcare Conference will occur from March 8-11, 2026, featuring 1x1 investor meetings [4] Company Overview - NervGen's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvement in function and quality of life in individuals with chronic spinal cord injury [5] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA for treating spinal cord injury [5] - The company is also developing a next-generation candidate, NVG-300, aiming to transform treatment paradigms for neurotraumatic and neurologic conditions with significant unmet medical needs [5]